1246524-08-2

Upstream product

• 1030524-56-1 6-chloro-2-(p-tolyl)-4H-benzo[d][1,3]oxazin-4-one 
• 874-60-2 4-methyl-benzoyl chloride 
• 635-21-2 5-chloroanthranilic acid 

Downstream Products

• 1609338-13-7 2-amino-N-(6-chloro-4-oxo-2-p-tolylquinazolin-3(4H)-yl)acetamide 
• 1609338-14-8 N-(6-chloro-4-oxo-2-p-tolylquinazolin-3(4H)-yl)-2-hydrazinylacetamide 
• 1609338-15-9 11-chloro-7-p-tolyl-2,3-dihydro-[1,2,4,5]tetrazepino[2,3-c]quinazolin-4(5H)-one 
• 1609338-12-6 2-chloro-N-(6-chloro-4-oxo-2-p-tolylquinazolin-3(4H)-yl)acetamide 
• 1609338-16-0 3-(benzylideneamino)-6-chloro-2-p-tolylquinazolin-4(3H)-one 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of some novel substituted quinazolines as antitumor agents

A novel series of 6-chloro-2-p-tolylquinazolinone and substituted-(4- methylbenzamido)benzamide (1-20) were designed, synthesized and evaluated for their in-vitro antitumor activity. Compounds 3, 14 and 16 possessed remarkable broad-spectrum antitumor activity. Compound 16 was found to be a particularly active growth inhibitor of the renal cancer (GI50 = 4.07 μM), CNS cancer (GI50 = 7.41 μM), ovarian cancer (GI50 = 7.41 μM) and non-small cell lung cancer (GI50 = 7.94 μM). Compound 16 ranks as nearly 1.5-fold more potent (mean GI50 = 15.8 μM) compared to 5-FU (mean GI50 = 22.6 μM).

Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: Molecular docking study

Novel derivatives of quinazoline (1-27) have been synthesized and tested for their antitumor activity against three tumor cell lines among these cell lines the human breast carcinoma cell line (MCF-7) in which EGFR is highly expressed. All tested compound